- Home
- THTX vs BIOA Comparison
THTX vs BIOA Comparison
Compare THTX & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THTX
- BIOA
- Stock Information
- Founded
- THTX 1993
- BIOA 2015
- Country
- THTX Canada
- BIOA United States
- Employees
- THTX N/A
- BIOA N/A
- Industry
- THTX Biotechnology: Pharmaceutical Preparations
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- THTX Health Care
- BIOA Health Care
- Exchange
- THTX Nasdaq
- BIOA Nasdaq
- Market Cap
- THTX 144.8M
- BIOA 155.2M
- IPO Year
- THTX N/A
- BIOA 2024
- Fundamental
- Price
- THTX $3.29
- BIOA $4.80
- Analyst Decision
- THTX Hold
- BIOA Hold
- Analyst Count
- THTX 1
- BIOA 4
- Target Price
- THTX N/A
- BIOA $5.67
- AVG Volume (30 Days)
- THTX 372.3K
- BIOA 162.7K
- Earning Date
- THTX 10-09-2025
- BIOA 11-06-2025
- Dividend Yield
- THTX N/A
- BIOA N/A
- EPS Growth
- THTX N/A
- BIOA N/A
- EPS
- THTX N/A
- BIOA N/A
- Revenue
- THTX $84,378,000.00
- BIOA $3,863,000.00
- Revenue This Year
- THTX N/A
- BIOA N/A
- Revenue Next Year
- THTX $13.76
- BIOA N/A
- P/E Ratio
- THTX N/A
- BIOA N/A
- Revenue Growth
- THTX 2.19
- BIOA N/A
- 52 Week Low
- THTX $1.12
- BIOA $2.88
- 52 Week High
- THTX $3.31
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- THTX 70.36
- BIOA 53.70
- Support Level
- THTX $3.26
- BIOA $4.55
- Resistance Level
- THTX $3.31
- BIOA $5.09
- Average True Range (ATR)
- THTX 0.02
- BIOA 0.23
- MACD
- THTX -0.00
- BIOA 0.00
- Stochastic Oscillator
- THTX 71.43
- BIOA 55.88
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.